Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03856229Not ApplicableEnrolling By Invitation

Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS

Role: lead

NCT03957369Completed

Primary Resistance in HIV Patients in Colombia

Role: collaborator

NCT04475991Phase 2Terminated

Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults

Role: collaborator

NCT02555800Phase 2Unknown

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

Role: lead

NCT01296815Phase 2Completed

Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

Role: lead

All 5 trials loaded